A meiotic B-type cyclin selectively drives mitotic progression and fidelity in cancer cells
- 1University of California, Irvine
Abstract
Cell cycle transitions are driven by cyclins in complex with cyclin-dependent kinases (CDK). Here, we demonstrate that cyclin B3, an evolutionarily divergent B-type cyclin previously thought to function exclusively in female meiosis, is expressed in mitotic cells and interacts with both CDK1 and CDK2. We show that cyclin B3-CDK1/2 is essential for timely mitotic progression by ensuring proper chromosome alignment and stable kinetochore-microtubule interactions, while its overexpression accelerates mitosis and improves chromosome alignment kinetics. Through phospho-mass spectrometry, we identify several kinetochore and mitotic spindle components as substrates of cyclin B3-CDK1/2 in mitosis. Notably, cyclin B3 depletion disrupts mitotic progression in most cancer cell lines tested - including colorectal, osteosarcoma, and breast cancer models - while non-transformed cells are largely unaffected. These findings identify cyclin B3-CDK1/2 as a novel driver of mitotic progression and reveal a preferential dependency in a subset of cancer cells that may represent a potential therapeutic vulnerability.
Related
- Adolescent psychological stress impairs spermatogenesis by disrupting meiotic progression in male mice
- Pharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
- Targeting the CDK4-Cyclin D Complex: A New Generation of Selective Kinase Inhibitors for Cancer Therapy
- Aberrant Accumulation of Cyclin D1 Rewires Glutamine Metabolism and Generates a Metabolic Vulnerability in Squamous Cell Carcinoma
- Transcriptional cyclin-dependent kinases as therapeutic targets in bone metastasizing cancers
BibTeX
@misc{kizhedathu2026meiotic,
title = {{A meiotic B-type cyclin selectively drives mitotic progression and fidelity in cancer cells}},
author = {A. Kizhedathu and A. C. N. Nguyen and C. Yu and S. Moghareh and V. Tran and P. Mousaian and J. Vertiz and C. A. Benavente and L. Huang and P. Lara-Gonzalez},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.28.754947},
url = {https://www.biorxiv.org/content/10.64898/2026.09.28.754947v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - A meiotic B-type cyclin selectively drives mitotic progression and fidelity in cancer cells
AU - A. Kizhedathu
AU - A. C. N. Nguyen
AU - C. Yu
AU - S. Moghareh
AU - V. Tran
AU - P. Mousaian
AU - J. Vertiz
AU - C. A. Benavente
AU - L. Huang
AU - P. Lara-Gonzalez
PY - 2026
DA - 2026/09/28
PB - bioRxiv
DO - 10.64898/2026.09.28.754947
UR - https://www.biorxiv.org/content/10.64898/2026.09.28.754947v1
AB - Cell cycle transitions are driven by cyclins in complex with cyclin-dependent kinases (CDK). Here, we demonstrate that cyclin B3, an evolutionarily divergent B-type cyclin previously thought to function exclusively in female meiosis, is expressed in mitotic cells and interacts with both CDK1 and CDK2. We show that cyclin B3-CDK1/2 is essential for timely mitotic progression by ensuring proper chromosome alignment and stable kinetochore-microtubule interactions, while its overexpression accelerates mitosis and improves chromosome alignment kinetics. Through phospho-mass spectrometry, we identify several kinetochore and mitotic spindle components as substrates of cyclin B3-CDK1/2 in mitosis. Notably, cyclin B3 depletion disrupts mitotic progression in most cancer cell lines tested - including colorectal, osteosarcoma, and breast cancer models - while non-transformed cells are largely unaffected. These findings identify cyclin B3-CDK1/2 as a novel driver of mitotic progression and reveal a preferential dependency in a subset of cancer cells that may represent a potential therapeutic vulnerability.
ER -